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SUITABILITY AND REPEATABILITY OF A
PHOTOSTRESS RECOVERY TEST DEVICE,
THE MACULAR DEGENERATION
DETECTOR (MDD-2), FOR DIABETES AND
DIABETIC RETINOPATHY ASSESSMENT
JAMES LOUGHMAN, PHD,*† MATTHEW RATZLAFF, BSC,‡ BRITTANY FOERG, BSC,*
PAUL CONNELL, MD‡
Background: Diabetic retinopathy can result in impaired photostress recovery time
despite normal visual acuity and fundoscopic appearance. The Macular Degeneration
Detector (MDD-2) is a novel flash photostress recovery time device. In this study, we
examine the repeatability of the MDD-2 in normal and diabetic subjects.
Methods: One hundred and ninety one (90 women, 101 men) subjects were recruited
and divided into 1 of the 3 study groups (normal controls, n = 40; diabetes no retinopathy,
n = 98; nonproliferative diabetic retinopathy, n = 53). Photostress recovery time was mea-
sured three times in the study eye using the MDD-2, each measurement separated by
a 5-minute interval.
Results: Repeated measures analysis of variance revealed no statistically significant
learning or fatigue effects on intrameasurement repeatability for any group. Photostress
recovery time measures were broadly similar and typically not statistically significantly
different between study groups. The coefficient of repeatability reached clinically accept-
able levels once the initial photostress recovery time measure, which demonstrated
increased variability and latency compared with all subsequent measures, was excluded.
Conclusion: The MDD-2 seems to provide repeatable photostress recovery time
measurements among naive diabetic subjects. The device does not, however, seem
capable of differentiating normal and nonproliferative diabetic eyes, and would not be
suitable for inclusion in diabetic retinopathy screening protocol.
RETINA 0:1–8, 2013
The global population is aging and life expectancyis increasing. Current lifestyle habits are leading to
an epidemic in obesity and cardiovascular disease,
including diabetes.1–5 Even in developing countries,
where diabetic retinopathy (DR) has not been a histor-
ically significant cause of blindness, the demographic
change and westernization of dietary and lifestyle
habits are creating an emerging disease profile that
includes diabetes and DR.6–8
The development of ocular complications in diabe-
tes is related to disease control and longevity. After
20 years, more than 75% of patients will have some
form of DR.9 It has been suggested, however, that
visual loss associated with the development of DR
could be reduced for the majority of patients with
proper and vigilant monitoring of diabetic eyes, and
prompt treatment initiation where required.10 Earlier
detection and more effective management can delay
disease progression, prevent debilitating sight loss,
and thereby reduce future dependency on health care
services. This is particularly important in light of the
likely increase in visual impairment and blindness set
to accompany increasing diabetes prevalence,11 and
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the substantial personal and societal (including eco-
nomic) costs associated with such avoidable visual
impairment.12 The possibilities for retarding disease
progression including recent advances in pharmaco-
logic management of diabetic maculopathy, best
applied at the earliest stages of the development of
abnormal pathology, further increase the priority that
should be afforded to effective disease monitoring.13–15
Diabetic maculopathy is the most common cause of
visual loss in diabetic patients. Visual acuity represents
the most widely used test of visual, and in particular
macular, function. Visual acuity alone, however, is an
inadequate biomarker of visual function in macular
disease, and can be relatively insensitive to the impact
of functional deterioration in the early stages of diabetic
macular disease.16,17 Alternative tests of visual function
have, however, proved capable of isolating macular
functional loss in cases where visual acuity remains
normal, including contrast sensitivity,17–20 color
vision,21,22 and chromatic sensitivity.23,24 In particular,
photostress recovery has also been shown to be
adversely affected by diabetic macular disease.25–27
Photostress recovery time (PSRT) describes the time
required to regain normal visual function following
exposure to intense light that bleaches the visual
pigments and saturates the response of the macular
photoreceptors, and thereby effects a transient loss of
vision.28 Normal recovery is dependent on the under-
lying retinal photoreceptor and pigment epithelium
function.29 The Macular Degeneration Detector
(MDD-2) is a novel flash photostress recovery device.
This device has previously been shown to be capable
of detecting functional vision loss in age-related mac-
ular degeneration and diabetic maculopathy.25 It has
also been shown to provide reproducible measure-
ments in a young healthy population.30 No previous
study, however, has explored the learning effect and
repeatability of test measures among a diabetic popu-
lation without maculopathy. In this study, we examine
the repeatability of the MDD-2 in such a population in
comparison to an age-matched normal population, as
a means to determine 1) whether the device can pro-
vide clinically acceptable repeat test measures, and 2)
whether diabetes, or nonproliferative DR in the
absence of maculopathy, has an effect on PSRT com-
pared with normal controls (NCs).
Materials and Methods
One hundred and ninety one subjects (90 women,
101 men) participated in this study which received
local Research Ethics committee approval. Informed
consent was obtained from each volunteer, and the
experimental procedures adhered to the tenets of the
Declaration of Helsinki.
Diabetic subjects were recruited from eligible retinal
clinic attendees at the Mater Misericordiae hospital,
Dublin, Ireland. Normal (nondiabetic) subjects were
recruited at the National Optometry Centre at Dublin
Institute of Technology, Dublin, Ireland. Subjects
were assigned, on the basis of their diabetic and ocular
health status, to 1 of the 3 study groups: diabetes no
retinopathy, n = 98 (48 women, 50 men); nonProlifer-
ative DR, n = 53 (20 women, 33 men); NC, n = 40 (22
women; 18 men). The following diabetes relevant
information was recorded for each diabetic participant:
diabetes duration (years), diabetes type, diabetes med-
ication, and retinopathy grade (graded according to
modified two-field Early Treatment Diabetic Retinop-
athy Study protocol; grade range, R0 M0–R2 M0).31
Generic inclusion criteria were as follows: subjects
were to be over 18 years of age, and have LogMAR
visual acuity better than 0.2 (6/9) in the study eye; and
subjects were required to be able to identify the
baseline numeric stimulus presented by the device
without their refractive correction. For normal sub-
jects, exclusion criteria included any sign of retinal or
ocular abnormality and the presence of Type 1 or Type
2 diabetes. Subjects with diabetes were excluded if
they exhibited signs of ocular comorbidity (e.g., age-
related macular degeneration, glaucoma, cataract), had
previously undergone any form of treatment for DR or
diabetic maculopathy, or if they exhibited any signs of
proliferative retinopathy or maculopathy.
A computer generated LogMAR test chart (Thom-
son 2000 Pro; Thomson Software Solutions, Hatfield,
United Kingdom) was used to determine LogMAR
acuity. Iris color was recorded using an iris color
classification scheme, with iris color matched to
standard color photographs and classified into one of
the five color categories (gray, blue, green, light
brown, brown) as described by Seddon et al.32 Slit-
lamp indirect ophthalmoscopy and retinal photography
(Zeiss Visucam Pro NM [Carl Zeiss Meditec,
Germany], 45° field, 1 disk and 1 macula centered
photograph) was conducted for all subjects.
Photostress recovery time was measured using the
MDD-2 Macular Degeneration Detection device
(Icandy Digital, LLC, FL). The MDD-2 is a relatively
simple device, comprising a spectrally broadband
xenon flash light source (with good short-term
[1%] and long-term [3%] output stability), a UV
and IR filter, and focusing (+8 diopters) lens. The test
involves accurate identification (postflash photostress)
of a large (0.41 radian/23.49° angular subtense) ran-
domly generated number between 0 and 9. The target
is viewed through a 12-mm central aperture in the
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flash tube. The 200-msecond duration flash is gener-
ated by a xenon flash source, mounted inside the flash
tube within the subject’s field of view, extending
across an angular subtense of 38° of visual angle.
All subjects recruited into the study were naive to
the MDD-2 test. The nature of the test and stimuli
were described in detail to each subject, and the
subject was requested to confirm their understanding
of the task. The flash tube was positioned against the
test eye, and the subject was required to correctly
identify a baseline, prephotostress, numeric stimulus
without their refractive correction. Subjects were
instructed to fixate centrally at the position of the
prebleach stimulus, and to avoid blinking at the onset
of the photostress flash. When ready to commence the
test proper, the subject pressed a button on the device
that initiated three concurrent processes: the arc flash
photostress, the photostress recovery timer, and a new
random number, which was displayed continuously
until a recognition response was given. The subject
was required to verbally identify the new number, and
simultaneously, to press the same button on the device
to cease the test at the instant when vision recovered
sufficiently to allow number recognition.
The study eye was selected as the eye with better
visual acuity, or in cases of equal acuity, the right eye
was selected as standard. The PSRT measurement was
conducted in the study eye, and repeated on two
further occasions, each separated by a 5-minute
interval, providing a set of 3 PSRT measures (PSRT
1, PSRT 2, and PSRT 3). Incorrect identification of the
test stimulus, at baseline, resulted in exclusion from
the study. A single incorrect response during the test
phase was permitted (result discarded and test repeated
after a 5-minute interval), but a second incorrect
response resulted in exclusion from the study. Where
both eyes met the study inclusion criteria, PSRT
measures were also recorded for the fellow eye to
facilitate intereye comparison.
The statisticalAQ : 2 software package SPSS (version 20;
SPSS, Inc, Chicago, IL) was used for analysis. One-
way analysis of variance was used to test for differ-
ences in study parameters between the groups.
Repeated measures analysis of variance was used to
test for learning or fatigue effects that might confound
analysis of repeat measures in the study eye. Paired
samples t-tests were used to test for PSRT differences
between eyes. Pearson correlation coefficients were
calculated to investigate the relationship between
sequential measurements, and between eyes. Bland–
Altman analysis and plots, and the limits of agreement,
were used to quantify the agreement between repeat
measures of PSRT.33 Intrameasurement repeatability is
expressed as a coefficient of repeatability, which was
calculated as the standard deviation of the mean dif-
ference between measurements, and multiplied by
1.96. A 5% significance level was used throughout
the analysis.
Results
All participants successfully identified the baseline
pretest stimulus and advanced to the test phase of the
investigation. Demographic and health status informa-
tion, stratified according to study group, is presented in
Table T11.
Intergroup Analysis
The mean (±standard deviation) visual acuity of
each study group was: diabetes no retinopathy = log-
MAR −0.04 (±0.10); DR = logMAR −0.06 (±0.12);
NC = logMAR −0.06 (±0.10). One-way analysis of
variance revealed no statistically significant differen-
ces in sex (P = 0.23), iris color (P = 0.34), or visual
acuity (P = 0.70) between the 3 study groups. Statis-
tically significant differences were observed between
groups, however, for age (P , 0.01) and diabetes
duration (P , 0.01).
Mean (±standard deviation) PSRT for each of the
3 measurements in the study eye is presented in T2Table 2,
and demonstrates a trend toward improved PSRT with
each sequential measurement in the study eye, with the
most substantial improvement in PSRT immediately
after the baseline test, between PSRT 1 and 2.
A statistically significant difference between groups
was observed for PSRT 2 (P = 0.01), but not for PSRT
1 (P = 0.13) or PSRT 3 (P = 0.09) measures. Posthoc
analysis (Scheffe test) isolated the variance in the
PSRT 2 measure to the nonproliferative DR group,
whose PSRT times were statistically significantly
shorter than those of the NC (P = 0.01) and diabetes
no retinopathy (P = 0.04) groups. No other pairwise
differences were observed.
Intragroup Analysis
Repeated measures analysis of variance, using
a general linear model approach with age, sex, and
iris color as covariates, demonstrated no significant
differences between repeat PSRT measures for all
subjects combined and for individual study groups
(Combined: P = 0.86; NC: P = 0.51; diabetes no
retinopathy: P = 0.74; DR: P = 0.20—Greenhouse–
Geisser correction for sphericity violation applied to
all), which suggests the absence of a significant learn-
ing or fatigue effect, despite the gradual shortening of
successive PSRT measures for each study group.
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Pearson’s correlation revealedAQ : 3 a moderate-to-strong
and statistically significant relationship between the 3
PSRT measures in the study eye, for all subjects com-
bined (r = 0.44–0.70, P , 0.01 for all;F1 Figure 1) and
for grouped comparisons (r = 0.39–0.71, P = 0.01–
0.04). Paired samples t-tests revealed no PSRT differ-
ences between the study and fellow eye for any sub-
group (P . 0.05 for all).
Bland–Altman analysis and plots were used to assess
the agreement between successive PSRT measures in
the study eye. The difference in mean recovery time
between PSRT 2 and 3 in the study eye for all subjects
(0.34 seconds), and limits of agreement are presented in
FigureF2 2. The coefficient of repeatability for all subjects
was 4.01 seconds, and for 59% of the subjects, the
difference in recovery time between PSRT 2 and PSRT
3 was#1 second (#2 seconds for 80% of the subjects),
indicating good within-eye repeatability. The difference
in mean recovery time and coefficient of repeatability,
calculated for individual study groups, closely aligns
to the overall figures (mean differences range, 0.2–
0.6 seconds; coefficient of repeatability range, 3.92–
4.12 seconds). When comparing PSRT 1 with PSRT
3, the mean difference between recovery time measures
is significantly larger (range, 2.4–3.4 seconds across
study groups) and the coefficient of repeatability is sig-
nificantly poorer for the overall group at 6.29 seconds,
and across individual study groups. In addition, differ-
ences between recorded recovery times were#1 second
for only 38% of the subjects, indicating poorer repeat-
ability when using the initial PSRT 1 as the baseline
value.
Relationship Between Photostress Recovery Time
and Other Variables
Independent samples t-tests revealed no significant
effect of gender (P = 0.26–0.96 across study groups),
iris color (P = 0.06–0.98 across study groups), or dia-
betes type (P = 0.05–0.36 across study groups) on any
Table 1. Demographic, Anthropometric and Health Status Information of Study ParticipantsAQ : 9
Characteristic NC (N = 40)
Diabetes No
Retinopathy (N = 98)
Diabetes
Nonproliferative




Male 45 51 62 0.23
Female 55 49 38
Age (Mean ± SD, years) 56 ± 10 56 ± 16 49 ± 10 ,0.01
Iris Color (%)
Blue 43 56 53 0.34
Brown 15 16 19
Hazel 25 14 11
Green 17 14 19
Diabetes Type (%)
Type 1 0 DM = 20 55 ,0.01
Type 2 0 DM = 80 45
Diabetes Medication (%)
Insulin 0 20 47 ,0.01
Oral HypoG 0 64 40
Combined 0 11 13
None 100 5 0
Diabetes Duration (Mean ± SD,
years)
0 7.48 ± 6.62 15.63 ± 9.56 ,0.01
Visual Acuity −0.06 ± 0.10 −0.04 ± 0.10 −0.06 ± 0.12 0.70
ANOVA, analysis of variance; Oral HypoG, oral hypoglycemics; SD, standard deviation.
Table 2. Mean PSRT For the First (PSRT 1), Second (PSRT 2), and Third (PSRT 3) Measurements in the Study Eye Across
Study Groups





Mean ± SD (s) Mean ± SD (s) Mean ± SD (s) P
PSRT 1 9.94 ± 3.56 8.98 ± 3.52 8.33 ± 3.27 0.13
PSRT 2 7.63 ± 2.85 7.16 ± 2.84 6.04 ± 1.44 0.01
PSRT 3 7.03 ± 2.41 6.77 ± 2.91 5.90 ± 2.36 0.09
ANOVA, analysis of variance; s, seconds; SD, standard deviation.
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Fig. 1. Scatterplot demonstrat-
ing a strong and statistically
significant correlation between
PSRT 2 and PSRT 3 measures
for all subjects.
Fig. 2. Bland–Altman plot
showing mean difference and
95% limits of agreement (0.34 ±
4.01 seconds) for repeat meas-
urements in the study eye (PSRT
2 and PSRT 3) for the overall
subject group.
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of the 3 PSRT measures. Pearson’s correlation, con-
trolling for age and diabetes duration, revealed no sig-
nificant relationship between PSRT and visual acuity
overall (r = −0.05, P = 0.54) and across study groups
(r = −0.03–0.09, P = 0.41–0.90). A statistically signif-
icant relationship was found, however, between PSRT
and age overall,F3 Figure 3 (r = 0.15–0.25, P = 0.001–
0.04), and for the NC subgroup for all 3 PSRT meas-
ures (r = 0.37–0.45, P = 0.003–0.04). For diabetes
subgroups, however, the relationship with age was
not statistically significant (P . 0.05), other than for
PSRT 1 measure in the DR subgroup (r = 0.34, P =
0.02).
Discussion
Photostress recovery devices including the Scotom-
eter,34 the Brightness Acuity Test,35 and the Eger
Macular Stressometer,36 have been developed for the
assessment of ocular health but none have translated
into routine clinical practice. More traditional devices
including the ophthalmoscope and automated perime-
ter have also been adapted to provide PSRT meas-
ures,37,38 but as of yet no device or technique has
provided a universally acceptable and repeatable
PSRT test that is capable of detecting disease presence
or monitoring progression.
It has previously been shown that PSRT is adversely
affected by conditions affecting the macula, including
central serous retinopathy,39 age-related macular
degeneration,25 and diabetic maculopathy.25–27 Dis-
ruption of the retinal pigment epithelium–retina rela-
tionship, because of serous retinal detachment or
macular edema for example, has been shown to be
an important factor in the prolongation of PSRT in
such macular disease.40 Importantly, PSRT deficits
have been observed in asymptomatic subjects where
visual acuity is relatively preserved, indicating that
a suitably designed test might provide an effective
indicator of early disease or disease progression.41
This study is the first to explore the effect of
diabetes including nonproliferative DR, on PSRT in
comparison to NCs, and to evaluate the repeatability of
PSRT measures among naive subjects with and
without nonproliferative DR. The trend toward shorter
PSRT measures on repeat testing is in general
agreement with previous observations among younger
participants, although the trends were not statistically
significant in this study.30 Similar trends have been
observed for other devices, such as the Eger Macular
Stressometer, which was shown to provide repeatable
results and a subtle shortening of PSRT on repeat
testing.36 The general recommendation, however, that
a single practice measure is sufficient to overcome any
possible learning effect, and thereby facilitates a valid
Fig. 3. Scatterplot demonstrat-
ing the relationship between age
and PSRT 3 for the overall
subject group.
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baseline PSRT measure would seem applicable across
both younger and older populations with and without
nonproliferative DR.
It is interesting to note the shorter PSRT measures
obtained in both diabetic subgroups, in particular the
DR group, when compared with NCs for all three
PSRT measures in the study eye. These differences
were largely nonsignificant from a statistical perspec-
tive, and certainly insignificant from a clinical per-
spective. The observed differences most likely reflect
the age differences observed between the study
groups, given that the DR group was statistically
younger than the other two groups, and that the NC
subgroup exhibited a positive and significant associ-
ation between PSRT and age. The age differences
observed in the NC subgroup, and for the overall study
sample, are in general agreement with previous
observations on the relationship between PSRT meas-
ures and age.34,41,42 In addition, the mean PSRT of the
NC group observed herein (7.03 ± 2.41 seconds for
PSRT 3) is longer than that previously observed in
a younger (mean age, 35 years) normal cohort using
the same device (5.11 ± 1.51 seconds for PSRT 3).30
In the absence of any age-defined normative values for
the device, such age dependency is of clinical rele-
vance and suggests that eye health practitioners should
interpret individual PSRT measures with caution,
except where evidence exists of intereye asymmetry
or elongation of PSRT over time on repeated meas-
ures. Of note, PSRT was also measured in the fellow
eye in this study where eligible and no intereye differ-
ences were observed for any PSRT measure, which
could prove diagnostic for unilateral disease.
These findings suggest that neither the diabetes
condition itself nor the presence of nonproliferative
DR as a consequence has an adverse effect on PSRT as
measured using this flash recovery device. The device
would not, therefore, seem capable of detecting the
presence of diabetes or nonproliferative DR, or distin-
guishing such eyes as distinct from those of normal
persons without diabetes. These findings are somewhat
in agreement with previous observations of the impact
of early DR on macular recovery dynamics made using
alternate methods. The recovery times among subjects
with background DR were comparable with those
observed among NCs using a macular photostress
test,43 whereas the Eger Macular Stressometer proved
similarly incapable of detecting functional losses asso-
ciated with DR and other ocular diseases.36 Macular
recovery measured using nyctometry has, however,
been shown to be impaired in early DR.26,27
The presence of diabetic maculopathy, however, has
previously been shown to elongate PSRT measures
and also to cause a prolongation of PSRT on 5-minute
repeat testing. Among subjects with diabetic macular
edema, PSRT measures using the same MDD-2 device
averaged in excess of 20 seconds, more than 3 times
the average measures obtained here, for diabetic
subjects without maculopathy.25 These allied findings
suggest that the flash recovery device is sensitive to
macular changes, and furthermore, that photostress
losses in patients with diabetes are particular to the
development of diabetic maculopathy, the most com-
mon cause of visual impairment. This is an important
finding given that the instrument design is not intui-
tively suited to the isolation of macular function and
recovery dynamics (the flash area [38°] and stimulus
size [23°] extend significantly beyond the central mac-
ular area).
The findings of this study suggest that the MDD-2
may not be sensitive to diabetes, although the device
provides repeatable PSRT measures among normal
and diabetic subjects, with or without nonproliferative
DR. As such, the value of the device would seem
limited to the transition to more advanced diabetic or
other forms of maculopathy, and therefore it is not of
tremendous value as a DR screening tool. Further
research is required to determine whether the device is
a useful tool for longitudinal assessment of macular
function in diabetes and other ocular diseases that
present a risk to macular integrity, and whether it is
useful as an outcome measure in evaluating therapeu-
tic interventions.
Key words: photostress recovery, diabetic retinop-
athy, maculopathy, repeatability, MDD-2.
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